CAR T therapy provides long-lasting remissions in non-hodgkin lymphoma
Study shows most non-Hodgkin's lymphoma patients who achieve a remission lasting one year remain in remission for five years after receiving Novartis’ Kymriah™.
List view / Grid view
Study shows most non-Hodgkin's lymphoma patients who achieve a remission lasting one year remain in remission for five years after receiving Novartis’ Kymriah™.
The EMA’s human medicines committee (CHMP) recommended fifteen medicines for various approvals at its January 2020 meeting; with ten drugs receiving marketing authorisation recommendations and five receiving positive opinions for specific treatments.
The FDA has approved RUXIENCE (rituximab-pvvr), a biosimilar to Rituxan® (rituximab), for treatment of non-Hogkin’s lymphoma and other conditions.